Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Jackman

Showing results (21-30 of 53) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancersKimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, et al.
Cancer|April 17, 2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancerPeter C Lo, Suzanne E Dahlberg, Mizuki Nishino, et al.
Cancer|August 8, 2013
Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
Lung Cancer (Amsterdam, Netherlands)|December 21, 2012
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
American Journal of Clinical Pathology|May 18, 2010
EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistryLynette M Sholl, Yun Xiao, Victoria Joshi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertionsGeoffrey R Oxnard, Peter C Lo, Mizuki Nishino, et al.
Journal of Oncology Practice|March 7, 2017
Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung CancerDavid M Jackman, Yichen Zhang, Carole Dalby, et al.
The Oncologist|June 3, 2011
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLCRaymond H Mak, Elizabeth Doran, Alona Muzikansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibDavid M Jackman, Alison J Holmes, Neal Lindeman, et al.
AJR. American Journal of Roentgenology|August 24, 2010
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapyMizuki Nishino, David M Jackman, Hiroto Hatabu, et al.
Pageof 6

Showing results (21-30 of 53) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancersKimio Yonesaka, Kreshnik Zejnullahu, Neal Lindeman, et al.
Cancer|April 17, 2015
Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancerPeter C Lo, Suzanne E Dahlberg, Mizuki Nishino, et al.
Cancer|August 8, 2013
Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionMizuki Nishino, Suzanne E Dahlberg, Stephanie Cardarella, et al.
Lung Cancer (Amsterdam, Netherlands)|December 21, 2012
Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsMizuki Nishino, Stephanie Cardarella, Suzanne E Dahlberg, et al.
American Journal of Clinical Pathology|May 18, 2010
EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistryLynette M Sholl, Yun Xiao, Victoria Joshi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 19, 2013
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertionsGeoffrey R Oxnard, Peter C Lo, Mizuki Nishino, et al.
Journal of Oncology Practice|March 7, 2017
Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung CancerDavid M Jackman, Yichen Zhang, Carole Dalby, et al.
The Oncologist|June 3, 2011
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLCRaymond H Mak, Elizabeth Doran, Alona Muzikansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2006
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinibDavid M Jackman, Alison J Holmes, Neal Lindeman, et al.
AJR. American Journal of Roentgenology|August 24, 2010
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapyMizuki Nishino, David M Jackman, Hiroto Hatabu, et al.
Pageof 6